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Most authors recommend a quick freeze and slow thaw 
method of tissue destruction. Slow cooling produces extra-
cellular ice, but this is not as damaging as rapid cooling that 
produces intracellular ice formation. With slow thawing, 
an increased concentration of electrolytes and recrystalli-
zation occurs, which is also damaging to cells. Thus the 
rate of rewarming, or thaw, should proceed slowly [1].
Cryoblasting successfully achieves the quick freeze and 
slow thaw desired for destruction of thicker lesions. To 
our current knowledge, there is only one previous report 
related to cryoblast for verrucae [2]. Callaway et al. showed 
that cryoblast can achieve a deeper ice ball compared with 
classic cryosurgery on a gelatin model [2]. Cryoblast is a 
technique which has a short duration of freeze giving pain 
relief and no difference of complications compared with 
classical methods. In the present study, we showed that 
cryoblast is signiﬁ cantly more effective than cryo-spray. 
Although we expected more scarring with cryoblasting, 
there was no difference from the scarring resulting from 
cryo-spray, as in the previous study [2].
Cryoblast could be an alternative method in the treatment 
of plantar verrucae. Controlled trials comparing cryoblast 
to cryospray are recommended for further conﬁ rmation. 
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Genital vitiligo-like depigmentation 
following use of imiquimod 5% cream
Imiquimod 5% cream is an immune response modiﬁ er, 
currently approved for use in external genital and perianal 
warts, superﬁ cial basal cell carcinoma and actinic kerato-
ses. The anti-viral and anti-tumoral activity seems to be 
dependent on focal activation of the immune system with 
induction, synthesis and release of cytokines, such as inter-
feron-alpha, interleukin-12 and tumor necrosis factor alpha 
[1]. This intense immune reaction is responsible for local 
side-effects, such as erythema, edema, erosions and crust-
ing. Post-infl ammatory pigmentary change has already 
been described as a possible complication, which is usu-
ally reversible. The induction of vitiligo-like depigmenta-
tion has been reported very rarely, but assumes importance 
due to the expanding uses of this medication [2-4].
We report a 26-year-old Caucasian male, with condyloma 
accuminata of the penis, treated initially with cryotherapy 
with only mild improvement. Imiquimod 5% cream (three 
times weekly) was used without signiﬁ cant side effects, 
except for moderate erythema and edema. After 12 weeks 
of continuous use, there was a complete resolution of 
lesions, without any pigmentary change. New lesions 
appeared and imiquimod was again used for 16 weeks, 
with a moderate to severe infl ammatory reaction. Areas of 
vitiligo-like depigmentation developed in the areas treated 
with imiquimod, and have remained stable for 18 months, 
much to the distress of the patient (fi gure 1). There was no 
previous history of vitiligo or other depigmentated areas 
elsewhere and no changes in thyroid function or autoim-
munity were detected. The patient refused a biopsy in the 
affected area.
The pathogenesis of vitiligo is still a matter of debate, with 
some evidence suggesting a T-cell mediated autoimmune 
reaction against melanocytes. The induction of vitiligo 
after skin trauma (Koebner effect) is not uncommon, but 
usually occurs in patients with a previous history of the 
disease. Theoretically, the ability of imiquimod to induce 
an immune response against infections and tumours may 
also be responsible for creating an environment in which 
the immune system would respond against melano-
cytic antigens [5]. The activation of epidermal cytokines 
(IL-6 and IL-8) and interferon-alpha induced by imiqui-
mod might have played a pathogenic role in the induction 
of vitiligo in our patient, through local activation of a cyto-
toxic T-cell response [6].
In conclusion, the depigmentation areas may represent the 
local induction of vitiligo, as a consequence of the immu-
nological reaction triggered by imiquimod. This report has 
Figure 1. Vitiligo-like depigmentation after imiquimod for 
genital warts, stable for 18 months.
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a long follow-up period (18 months), suggesting that in 
some patients the depigmentation might be long-lasting or 
even permanent. Although uncommon, physicians must be 
aware of this potential side-effect, especially when using 
the product on visible areas. 
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Investigation for the leptin 1 and LEP 
G2548A gene polymorphism in psoriasis
Since leptin is thought to play a role in immune functions 
[1] and an increased risk ofobesity and operation of a Th1 
type of cell mediated immune response have been docu-
mented in psoriasis; we aimed to investigate serum leptin 
levels and the effects of G2548A leptin gene polymor-
phism on serum leptin levels in patients with psoriasis.
Materials and methods
Sixty-ﬁ ve patients with psoriasis and 64 healthy volunteers 
were included in this study. Family history of psoriasis, 
age of onset (before and after 40 years of age), duration of 
the disease, type of psoriasis (plaque psoriasis versus oth-
ers), psoriasis area severity index (PASI), and activity of 
the disease (stable and unstable) were recorded.
Leptin was measured by the ELISA method and G2548A 
polymorphism of the LEP gene was analyzed by PCR 
ampliﬁ cation. Statistical analysis was performed by using 
SPSS 13.0 for Windows. A summary of data is presented 
as mean ± sd (median, minimum and maximum).
Results
There were 36 (55.4%) males and 29 (44.6%) females in 
the patient group and 41 (64.1%) males and 23 (35.9%) 
females in the control group. The mean ages of the patient 
and control groups were 45.17 ± 14.1 and 44.92 ± 14.2, 
respectively. There was no signiﬁ cant difference between 
the groups in terms of gender (x2 = 0.681, p = 0.409). 
Leptin levels were signiﬁ cantly correlated with BMI in both 
groups (r = 0.585, p = 0.0001 in patient group; r = 0.417, 
p = 0.0001 in control group; r = 0.518, p = 0.0001 for the 
whole group).
Leptin levels of female patients with psoriasis were signiﬁ -
cantly higher than control females. However, there was no 
signiﬁ cant difference between the diseased and control males 
(table 1, fi gure 1). Leptin levels were also signiﬁ cantly dif-
ferent between females and males in patient (p = 0.001) and 
control groups (p = 0.026). The difference was more signiﬁ -
cant for the patient group. There was no signiﬁ cant differ-
ence in leptin levels of patients with a positive and negative 
family history, age of onset (below and above 40), patients 
with different clinical types and activity of the  disease. 
Meaningful correlations were not found between leptin 
 levels and duration of the disease (r = – 0.041, p = 0.746), 
and PASI score (r = 0.115 and p = 0.361).
Leptin levels were not different between patients having 
GG, GA and AA genotypes (p = 0.424). Male patients with 
psoriasis did not show a signiﬁ cant difference in leptin lev-
els based on the coding alleles (p = 0.915). Although female 
patients with the AA genotype had lower levels of leptin, 
the difference was not statistically signiﬁ cant (p = 0.322).
Discussion
Apart from the role of leptin in weight control and immune 
modulation, increasing evidence suggests a role in some 
immunologically mediated pathophysiological conditions 
[1]. Although there is no study investigating serum leptin 
levels in psoriasis, it has been investigated in diseases in 
which a Th1 type of immune response plays an important 
role. Increased levels have been reported in active Behcet’s 
disease [2].
Correlation of serum leptin levels and G2548A poly-
morphism was investigated and subjects with an AA 
genotype were found to have signiﬁ cantly higher levels 
Table 1. Serum leptin levels and BMI according to genders in patient and control groups.
Mean leptin levels 
(med; min; max)
Signifi cance BMI (mean)
(med; min; max)
Signifi cance
Female patients 39.07 ± 30.88
(30.5; 1.3; 111.7)
P = 0.006 29.41 ± 7.28
(29; 17.58; 52.48)
P = 0.191




Male patients 7.19 ± 12.64
(4.95; –3.6; 55.2)
P = 0.417 27.08 ± 4.51
(26.91; 18.67; 37.18)
P = 0.931
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